The in vitro pharmacology of LY IGlar (LY2963016): a new insulin glargine product

被引：0
|
作者：
Moyers, J. S. [1 ]
Kahl, S. D. [1 ]
Ruan, X. [1 ]
Zhang, C. [1 ]
Farmen, M. W. [1 ]
Michael, M. D. [1 ]
Owens, R. A. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
519
引用
收藏
页码：S255 / S255
页数：1
相关论文
共 50 条
  • [1] The In Vitro Pharmacology of LY IGlar (LY2963016): A New Insulin Glargine Product
    Owens, Rebecca A.
    Kahl, Steven D.
    Ruan, Xiaoping
    Zhang, Chen
    Farmen, Mark W.
    Moyers, Julie S.
    Michael, M. Dodson
    [J]. DIABETES, 2015, 64 : A265 - A265
  • [2] Adult Low Blood Sugar Survey (ALBSS) and Insulin Treatment Satisfaction Questionnaire (ITSQ) Patient-Reported Outcomes (PROs) in LY2963016 Insulin Glargine (LY IGlar) and Lantus® Insulin Glargine (IGlar) Trials
    Perez-Nieves, Magaly
    Pollom, Robyn K.
    Delozier, Amy M.
    Duan, Ran
    Kabul, Samaneh
    Ilag, Liza L.
    [J]. DIABETES, 2015, 64 : A631 - A631
  • [3] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Lamb, Yvette N.
    Syed, Yahiya Y.
    [J]. BIODRUGS, 2018, 32 (01) : 91 - 98
  • [4] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Yvette N. Lamb
    Yahiya Y. Syed
    [J]. BioDrugs, 2018, 32 : 91 - 98
  • [5] LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union
    Altman, Jean-Jacques
    Chevalier, Nicolas
    Delemer, Brigitte
    Travert, Florence
    Benabbad, Imane
    [J]. PRESSE MEDICALE, 2018, 47 (10): : 854 - 866
  • [6] Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Yvette N. Lamb
    Yahiya Y. Syed
    [J]. BioDrugs, 2018, 32 : 181 - 181
  • [7] Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Riccardo Perfetti
    [J]. BioDrugs, 2018, 32 : 177 - 177
  • [8] Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Perfetti, Riccardo
    [J]. BIODRUGS, 2018, 32 (02) : 177 - 177
  • [9] Evaluation of immunogenicity of LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Huster, W. J.
    Costigan, T. M.
    Zielonka, J. S.
    Pollom, R. K.
    Prince, M. J.
    Konrad, R. J.
    [J]. DIABETOLOGIA, 2014, 57 : S397 - S398
  • [10] LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels
    Zhang, Xin
    Lam, Eric Chen Quin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Tan, Lai Hock
    Soon, Danny
    Linnebjerg, Helle
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (06): : 556 - 563
12345